<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC 2023 18_11-12_281</article-id>
<article-id pub-id-type="doi">10.15836/ccar2023.281</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
<subj-group subj-group-type="subheading"><subject>Biomarkers in Cardiology</subject></subj-group>
</article-categories>
<title-group>
<article-title>Biomarker Potential of Plasma Protein N-glycans in Coronary Artery Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3404-3837</contrib-id><name><surname>Blivajs</surname><given-names>Aleksandar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3333-486X</contrib-id><name><surname>Radovani</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3041-7718</contrib-id><name><surname>&#x0110;erek</surname><given-names>Lovorka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9473-2517</contrib-id><name><surname>Rudan</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Visentin</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1840-9560</contrib-id><name><surname>Lauc</surname><given-names>Gordan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0624-7170</contrib-id><name><surname>Gudelj</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Dubrava University Hospital</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
<aff id="aff2"><label>2</label><institution content-type="dept">Department of Biotechnology</institution>, <institution>University of Rijeka</institution>, <addr-line>Rijeka</addr-line>, <country country="hr">Croatia</country></aff>
<aff id="aff3"><label>3</label><institution>Genos Glycoscience Research Laboratory</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
<aff id="aff4"><label>4</label><institution content-type="dept">Faculty of Pharmacy and Biochemistry</institution>, <institution>University of Zagreb</institution>, <addr-line>Zagreb</addr-line>, <country country="hr">Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Ivan Gudelj, Sveu&#x010D;ili&#x0161;te u Rijeci, Odjel za biotehnologiju, Radmile Matej&#x010D;i&#x0107; 2, HR-51000 Rijeka, Croatia. / Phone: +385-99-5637-252 / E-mail: <email xlink:href="ivan.gudelj@uniri.hr">ivan.gudelj@uniri.hr</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>09</month><year>2023</year></pub-date>
<volume>18</volume>
<issue>11-12</issue>
<fpage>281</fpage>
<lpage>281</lpage>
<history>
<date date-type="received"><day>28</day><month>07</month><year>2023</year></date>
<date date-type="accepted"><day>27</day><month>09</month><year>2023</year></date>
</history>
<permissions>
<copyright-statement>Croatian Cardiac Society</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>plasma proteins</kwd><kwd>N-glycans</kwd><kwd>coronary artery disease</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction:</bold> Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), resulting from chronic inflammation of the coronary arteries due to the formation of atherosclerotic plaques, and its presence is a significant marker of adverse cardiovascular events. A growing body of research suggests that alterations in protein N-glycosylation are involved in the development of CVD through various mechanisms and have significant biomarker potential because of their sensitivity to changes that occur in the organism during inflammation-related conditions such as CVD (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>-<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>). Our aim was to determine whether the N-glycome of total plasma proteins is associated with CAD, because N-glycans are known to alter the effector functions of proteins, which may enhance their inflammatory response in CAD.</p>
<p><bold>Patients and Methods</bold>: In this study, we analysed the N-glycome of plasma proteins isolated from patients who underwent coronary angiography and classified into patients with confirmed coronary atherosclerosis and patients with clean coronaries. Proteins were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR) (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). Because previous studies have shown evidence of sexual dimorphism in CVD and significant sex differences in the association of N-glycans with CVD risk, we performed sex-stratified analysis of plasma N-glycans.</p>
<fig id="f1" position="float" fig-type="figure"><label>FIGURE 1</label><caption><p>Representative chromatogram of 2-AB labelled plasma protein N-glycans separated by HILIC&#x2013;UHPLC-FLR. The integration areas together with a major structure presented in each glycan peak are shown.</p></caption><graphic xlink:href="CC202318_11-12_281-f1"></graphic></fig>
<p><bold>Results:</bold> The results showed significant differences in plasma N-glycome composition in CAD. Lower abundance of complex biantennary galactosylated N-glycans with core fucose and, conversely, a higher abundance of highly branched (tri- and tetra-antennary) sialylated N-glycan structures with terminal fucose was shown to be associated with CAD.</p>
<p><bold>Conclusion:</bold> The obtained chromatograms shed light on the composition of plasma protein N-glycans in CAD and provided new insights into N-glycosylation changes in CAD. Overall, because of their sensitivity to changes that occur in an organism, protein N-glycosylation emerges as a significant factor in CAD and holds potential as a diagnostic tool, with glycan-based biomarkers showing promise for predicting cardiovascular health.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittenbecher</surname><given-names>C</given-names></name><name><surname>&#x0160;tambuk</surname><given-names>T</given-names></name><name><surname>Kuxhaus</surname><given-names>O</given-names></name><name><surname>Rudman</surname><given-names>N</given-names></name><name><surname>Vu&#x010D;kovi&#x0107;</surname><given-names>F</given-names></name><name><surname>&#x0160;tambuk</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Plasma N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.</article-title> <source>Diabetes Care</source>. <year>2020</year> March;<volume>43</volume>(<issue>3</issue>):<fpage>661</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2337/dc19-1507</pub-id><pub-id pub-id-type="pmid">31915204</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birukov</surname><given-names>A</given-names></name><name><surname>Plav&#x0161;a</surname><given-names>B</given-names></name><name><surname>Eichelmann</surname><given-names>F</given-names></name><name><surname>Kuxhaus</surname><given-names>O</given-names></name><name><surname>Hoshi</surname><given-names>RA</given-names></name><name><surname>Rudman</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.</article-title> <source>Diabetes Care</source>. <year>2022</year> November 1;<volume>45</volume>(<issue>11</issue>):<fpage>2729</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.2337/dc22-0833</pub-id><pub-id pub-id-type="pmid">36174116</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plav&#x0161;a</surname><given-names>B</given-names></name><name><surname>Szavits-Nossan</surname><given-names>J</given-names></name><name><surname>Blivajs</surname><given-names>A</given-names></name><name><surname>Rap&#x010D;an</surname><given-names>B</given-names></name><name><surname>Radovani</surname><given-names>B</given-names></name><name><surname>&#x0160;esto</surname><given-names>I</given-names></name><etal/></person-group> <article-title>The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.</article-title> <source>Biomolecules</source>. <year>2023</year> March 28;<volume>13</volume>(<issue>4</issue>):<fpage>605</fpage>. <pub-id pub-id-type="doi">10.3390/biom13040605</pub-id><pub-id pub-id-type="pmid">37189353</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
